| name | endo-paget-bisphosphonate-neoplasm-pretreatment |
| description | Pretreat with a potent bisphosphonate before surgery for pagetic bone neoplasm to reduce bleeding from adjacent pagetic bone. Triggers include suspicion of osteosarcoma or giant cell tumor in pagetic bone prompting orthopedic surgical referral. |
Pretreat with bisphosphonate before surgery for pagetic bone neoplasm
STEP 1 — Gather Information
Confirm Paget’s disease diagnosis (plain radiographs, bone scan), assess for neoplastic lesion (MRI/CT, biopsy if indicated), obtain orthopedic oncology evaluation, check serum ALP, bone turnover markers, renal function, calcium, vitamin D, and coagulation status. Document findings and proceed to risk assessment.
STEP 2 — Rule In / Rule Out
Is there suspicion of osteosarcoma or giant cell tumor arising in pagetic bone? If yes, proceed to surgical planning; if no, manage Paget’s disease per standard care and do not pursue neoplasm‑specific pretreatment.
STEP 3 — Classify or Stratify
If the orthopedic surgeon plans operative intervention (biopsy, resection, or stabilization), classify as needing preoperative bisphosphonate pretreatment; if surgery is not planned, no pretreatment is required for bleeding risk reduction.
STEP 4 — Decide
Administer a potent bisphosphonate (e.g., intravenous zoledronate 5 mg) 1–2 months preoperatively after correcting vitamin D deficiency and ensuring euglycemia and adequate renal function; if bisphosphonate is contraindicated, consider delaying surgery or using alternative hemostatic measures.
Clinical Guardrails / Mimics / Pitfalls
Do not give bisphosphonate in severe renal impairment (eGFR <35 mL/min), untreated hypocalcemia, or vitamin D deficiency; avoid high‑dose etidronate preoperatively due to fracture risk; do not delay definitive oncologic surgery unnecessarily; monitor for acute phase reaction, hypocalcemia, and atypical femoral fracture with long‑term use.
Concrete Clinical Example
A 68‑year‑old with known Paget’s disease of the femur presents with worsening pain; MRI shows a lytic lesion suggestive of osteosarcoma. Orthopedic oncology confirms suspicion and plans wide resection. Pretreatment with IV zoledronate 5 mg is given 6 weeks pre‑operatively after vitamin D supplementation and confirmation of normal renal function. Surgery proceeds with markedly reduced intraoperative bleeding and no transfusion requirement.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI: 10.1210/jc.2014-2910
